These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 32955826)

  • 21. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
    Lancet JE; Uy GL; Cortes JE; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Stone RM; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Hoering A; Banerjee K; Chiarella M; Louie AC; Medeiros BC
    J Clin Oncol; 2018 Sep; 36(26):2684-2692. PubMed ID: 30024784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
    Cortes JE; Lin TL; Uy GL; Ryan RJ; Faderl S; Lancet JE
    J Hematol Oncol; 2021 Jul; 14(1):110. PubMed ID: 34256819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
    Cortes JE; Goldberg SL; Feldman EJ; Rizzeri DA; Hogge DE; Larson M; Pigneux A; Recher C; Schiller G; Warzocha K; Kantarjian H; Louie AC; Kolitz JE
    Cancer; 2015 Jan; 121(2):234-42. PubMed ID: 25223583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
    Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
    Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances.
    Koenig KL; Sahasrabudhe KD; Sigmund AM; Bhatnagar B
    Genes (Basel); 2020 Jul; 11(8):. PubMed ID: 32722092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.
    Lin TL; Rizzieri DA; Ryan DH; Schiller GJ; Kolitz JE; Uy GL; Hogge DE; Solomon SR; Wieduwilt MJ; Ryan RJ; Faderl S; Cortes JE; Lancet JE
    Blood Adv; 2021 Mar; 5(6):1719-1728. PubMed ID: 33724305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.
    Gordon MJ; Tardi P; Loriaux MM; Spurgeon SE; Traer E; Kovacsovics T; Mayer LD; Tyner JW
    Leuk Res; 2017 Feb; 53():39-49. PubMed ID: 28013106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
    Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia.
    Murphy T; Yee KWL
    Expert Opin Pharmacother; 2017 Nov; 18(16):1765-1780. PubMed ID: 29017371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
    Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
    Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
    BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK.
    Mehta P; Campbell V; Maddox J; Floisand Y; Kalakonda AJM; O'Nions J; Coats T; Nagumantry S; Hodgson K; Whitmill R; Amott I; Flynn G; Taussig D; Zhao R; Cunningham N; Roset M; Cuadras D; Medalla G; Kuter H; Park S; Legg A; Khan AB
    Br J Haematol; 2024 Oct; 205(4):1326-1336. PubMed ID: 38977430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world experience with CPX-351 in high-risk acute myeloid leukemia.
    Lemoli RM; Montesinos P; Jain A
    Crit Rev Oncol Hematol; 2023 May; 185():103984. PubMed ID: 37028531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.
    Carol H; Fan MM; Harasym TO; Boehm I; Mayer LD; Houghton P; Smith MA; Lock RB
    Pediatr Blood Cancer; 2015 Jan; 62(1):65-71. PubMed ID: 25203866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
    van Eijkelenburg NKA; Rasche M; Ghazaly E; Dworzak MN; Klingebiel T; Rossig C; Leverger G; Stary J; De Bont ESJM; Chitu DA; Bertrand Y; Brethon B; Strahm B; van der Sluis IM; Kaspers GJL; Reinhardt D; Zwaan CM
    Haematologica; 2018 Sep; 103(9):1484-1492. PubMed ID: 29773602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC).
    Arber DA; Erba HP
    Am J Clin Pathol; 2020 Nov; 154(6):731-741. PubMed ID: 32864703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia.
    Villa KF; Ryan RJ; Chiarella M; Louie AC
    J Med Econ; 2020 Jul; 23(7):714-720. PubMed ID: 32188326
    [No Abstract]   [Full Text] [Related]  

  • 39. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
    Wei AH; Tiong IS
    Blood; 2017 Dec; 130(23):2469-2474. PubMed ID: 29051180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.
    Chiche E; Rahmé R; Bertoli S; Dumas PY; Micol JB; Hicheri Y; Pasquier F; Peterlin P; Chevallier P; Thomas X; Loschi M; Genthon A; Legrand O; Mohty M; Raffoux E; Auberger P; Caulier A; Joris M; Bonmati C; Roth-Guepin G; Lejeune C; Pigneux A; Vey N; Recher C; Ades L; Cluzeau T
    Blood Adv; 2021 Jan; 5(1):176-184. PubMed ID: 33570629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.